Abvc Biopharma (ABVC) Operating Expenses (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Operating Expenses came in at $1.6 million in Q1 2026, up 126.91% YoY from $693005.0 in Q1 2025, and down 28.49% on a QoQ basis from $2.2 million in Q4 2025.
Abvc Biopharma (ABVC) Operating Expenses (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Operating Expenses data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Operating Expenses rose 126.91% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 161.77% YoY) and the FY2025 annual result came in at $7.2 million, up 37.15% from the prior year.
- Operating Expenses slipped to $1.6 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $6.2 million in Q1 2022 to a low of $374794.0 in Q4 2023.
- A 5-year average of $2.1 million and a median of $2.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 312.14% — and 2023, when it tumbled 89.16%.
- Tracing ABVC's Operating Expenses over 5 years: stood at $3.5 million in 2022, then plunged by 89.16% to $374794.0 in 2023, then surged by 88.51% to $706530.0 in 2024, then surged by 211.23% to $2.2 million in 2025, then fell by 28.49% to $1.6 million in 2026.
- The last three Operating Expenses figures came in at $1.6 million (Q1 2026), $2.2 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | 779,526.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 779,526.00 |
| Mar 31, 2026 | 1.57 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 693,005.00 |
| Dec 31, 2024 | 706,530.00 |
| Sep 30, 2024 | 691,296.00 |
| Jun 30, 2024 | 977,059.00 |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 374,794.00 |
| Sep 30, 2023 | 2.14 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.97 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Sep 30, 2022 | 3.75 Mn |
| Jun 30, 2022 | 2.35 Mn |
| Mar 31, 2022 | 6.24 Mn |
| Dec 31, 2021 | 6.41 Mn |
| Sep 30, 2021 | 2.07 Mn |